Help us improve your experience, delivering more of what you want
WuXi Biologics (2269.HK), a global leading Contract Research, Development and Manufacturing Organization (CRDMO), today announced the release of its GMP phase I drug substance clinical manufacturing facility, MFG18, in Cranbury, New...
Become a Contributor
Advertise With Us
Terms & Conditions
Add this web page on your home screen for quick and easy access when you’re on the go.